Search research articles
Contact Us
Filters
Showing results (1-10 of 167) with videos related to
Page
of 17
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 11, 2016
It's Personal: Achieving Optimal Busulfan Exposure for All Patients
Brian T Hill
Oncotargets and Therapy
|
September 15, 2015
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
Brian T Hill, Matt Kalaycio
Leukemia & Lymphoma
|
October 14, 2011
Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma
Brian T Hill, John Sweetenham
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
Mark Roschewski, Brian T Hill
Journal of Virology
|
December 23, 2004
Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins
Brian T Hill, Jacek Skowronski
Expert Opinion on Biological Therapy
|
February 10, 2021
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Agrima Mian, Brian T Hill
Leukemia & Lymphoma
|
June 15, 2026
Beyond the dose: social determinants and treatment intensity in DLBCL
Ziad Abuhelwa, Brian T Hill
Expert Opinion on Biological Therapy
|
January 28, 2026
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
Rafaella Litvin, Brian T Hill
Expert Review of Hematology
|
September 14, 2022
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Brian T Hill, Brad Kahl
Current Hematologic Malignancy Reports
|
April 29, 2010
Acute myeloid leukemia: when to transplant in first complete remission
Brian T Hill, Edward A Copelan
Page
of 17
Search research articles
Search
Showing results (1-10 of 167) with videos related to
Sort By:
Page
of 17
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 11, 2016
It's Personal: Achieving Optimal Busulfan Exposure for All Patients
Brian T Hill
Oncotargets and Therapy
|
September 15, 2015
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
Brian T Hill, Matt Kalaycio
Leukemia & Lymphoma
|
October 14, 2011
Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma
Brian T Hill, John Sweetenham
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
Mark Roschewski, Brian T Hill
Journal of Virology
|
December 23, 2004
Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins
Brian T Hill, Jacek Skowronski
Expert Opinion on Biological Therapy
|
February 10, 2021
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Agrima Mian, Brian T Hill
Leukemia & Lymphoma
|
June 15, 2026
Beyond the dose: social determinants and treatment intensity in DLBCL
Ziad Abuhelwa, Brian T Hill
Expert Opinion on Biological Therapy
|
January 28, 2026
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
Rafaella Litvin, Brian T Hill
Expert Review of Hematology
|
September 14, 2022
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Brian T Hill, Brad Kahl
Current Hematologic Malignancy Reports
|
April 29, 2010
Acute myeloid leukemia: when to transplant in first complete remission
Brian T Hill, Edward A Copelan
Page
of 17